Bayer appeals $20.5 million Roundup ruling to California Supreme Court By Reuters

Bayer appeals $20.5 million Roundup ruling to California Supreme Court

© Reuters. FILE PHOTO: Logo and flags of Bayer AG are pictured outside a plant in Wuppertal, Germany

By Tom Hals

(Reuters) – Bayer AG (DE:) has asked California’s Supreme Court to review a decision awarding $20.5 million to a groundskeeper who claimed the company’s Roundup weedkiller caused his cancer, arguing the ruling was at odds with federal law and settled legal principles.

Bayer (OTC:), which acquired Roundup with its purchase of Monsanto (NYSE:) for $63 billion in 2018, said the July decision by the California Court of Appeal affirming a 2018 jury verdict in favor of Dewayne Johnson would be relied upon by other courts handling cases over the widely used herbicide.

A San Francisco jury initially awarded Johnson $289.2 million after finding the chemical glyphosate in Roundup caused his non-Hodgkin’s lymphoma.

The trial judge reduced that amount to $78.5 million and the Court of Appeal reduced that to $20.5 million.

“In this case, the Court of Appeal affirmed a verdict that severely punishes Monsanto for complying with federal law,” said the petition by the company, which has long said regulators have deemed glyphosate safe for use by humans.

Bayer said the high court should determine if a manufacturer of a federally approved herbicide can be liable under state law for failing to provide a cancer warning when the federal regulator determined federal law does not permit that warning.

Johnson also asked for a review of the Court of Appeal ruling reducing the damages.

He said the Supreme Court of California should decide if “loss of enjoyment of life” damages should include compensation for a shortened life expectancy caused by the wrongful act of the defendant.

Johnson’s case is separate from Bayer’s agreement on June 24 to pay up to $10.9 billion to settle nearly 100,000 lawsuits in the United States claiming that Roundup caused cancer.

If upheld, the verdict and payout could make it harder for Bayer to resolve lawsuits by other plaintiffs.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.